Thread: SNSS - Sunesis Pharmaceuticals Inc.

Results 1 to 5 of 5

  1. #1
    Armandoquaky
    Guest

    Default SNSS - Sunesis Pharmaceuticals Inc.

    Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. Its primary product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer in Phase 2 development stage. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in advanced platinum-resistant ovarian cancer patients. Sunesis Pharmaceuticals has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin. It was formerly known as Mosaic Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in South San Francisco, California.

    Sunesis Pharmaceuticals Inc.
    395 Oyster Point Boulevard
    Suite 400
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-266-3500
  2. #2
    Arrengal
    Guest

    Default

    Recent News:
    Sunesis Pharmaceuticals Initiates Phase II Clinical Trial of SNS-595 in Small Cell Lung Cancer

    Insider Buy Posted Yesterday:
    P 2006-03-17 2006-03-20
    16:10:18 SUNESIS PHARMACEUTICALS INC SNSS WARBURG PINCUS EQUITY PARTNERS LP
    WARBURG PINCUS & CO
    WARBURG PINCUS LLC
    Warburg Pincus Partners LLC 10% owner 805,153 $6.21 $5,000,000 3,626,875 Direct View

    P 2005-09-27 2006-02-14
    11:59:09 SUNESIS PHARMACEUTICALS INC SNSS BIOGEN IDEC INC
    BIOGEN IDEC MA INC 10% owner 714,286 $7 $5,000,002 2,912,022 Indirect View

    P 2005-09-30 2005-12-22
    21:47:48 SUNESIS PHARMACEUTICALS INC SNSS MAYFIELD IX
    MAYFIELD IX MANAGEMENT LLC
    MAYFIELD ASSOCIATES FUND III L P
    MAYFIELD VIII MANAGEMENT LLC
    UNGER WILLIAM D
    AUKEN WENDELL G VAN III
    FONG KEVIN A
    MYERS FRANK G JR
    DALAL YOGEN K
    HEIDRICH A GRANT III 10% owner 70,000 $7 $490,000 64,940 Direct
    Indirect View
    P 2005-09-30 2005-10-04
    19:14:56 SUNESIS PHARMACEUTICALS INC SNSS MAYFIELD IX
    MAYFIELD IX MANAGEMENT LLC
    MAYFIELD ASSOCIATES FUND III L P
    MAYFIELD VIII MANAGEMENT LLC
    UNGER WILLIAM D
    AUKEN WENDELL G VAN III
    FONG KEVIN A
    MYERS FRANK G JR
    DALAL YOGEN K
    HEIDRICH A GRANT III 10% owner 70,000 $7 $490,000 64,905 Direct
    Indirect View

    P 2005-09-30 2005-10-04
    17:39:40 SUNESIS PHARMACEUTICALS INC SNSS LEFF JONATHAN S(X) Director
    10% owner 445,000 $7 $3,115,000 1,379,127 Indirect View

    P 2005-09-30 2005-09-30
    18:12:28 SUNESIS PHARMACEUTICALS INC SNSS EVNIN ANTHONY B Director 135,000 $7 $945,000 649,955 Indirect View

    P 2005-09-27 2005-09-29
    15:58:30 SUNESIS PHARMACEUTICALS INC SNSS WARBURG PINCUS EQUITY PARTNERS LP
    WARBURG PINCUS & CO
    WARBURG PINCUS LLC
    Warburg Pincus Partners LLC 10% owner 445,000 $7 $3,115,000 2,821,722 Direct View
  3. #3
    ARRORNITET
    Guest

    Default

    Sunesis Pharmaceuticals Inc.
    341 Oyster Point Boulevard
    South San Francisco, CA 94080
    Phone: 650-266-3500
    Fax: 650-266-3505
    Web Site: http://www.sunesis-pharma.com

    Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for oncology, inflammatory diseases, and other unmet medical needs. Its fragment-based drug discovery approach, Tethering, combines with other drug discovery tools, such as structure-based design and medicinal chemistry to discover and develop novel therapeutics. The company’s pipeline includes SNS-595, a novel cell-cycle inhibitor for the treatment of cancer. Sunesis Pharmaceuticals was founded in 1998 and is headquartered in south San Francisco, California.
  4. #4

    Default

    add ANOTHER insider to the list:

    P 2006-03-17 2006-03-22
    21:56:55 SUNESIS PHARMACEUTICALS INC SNSS LEFF JONATHAN S(X) Director
    10% owner 805,153 $6.21 $5,000,000 3,626,875 Indirect View
  5. #5

    Default

    Oh boy, news today loooks good on this one, and with the tiny float it should FLY

    Sunesis Pharmaceuticals 4Q Rev $4.52M Vs $3.87M, +17%

    SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS - News), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2005. Total revenues for the fourth quarter were $4.5 million, with a net loss of $5.3 million. Total revenues for 2005 were $16.5 million, with a net loss of $27.5 million. As of December 31, 2005, cash, cash equivalents and marketable securities totaled $48.3 million and debt totaled $2.4 million.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts